Greenland Mines Ltd (GRML) stock
Close on Nov 20, 2026Market cap $40.92MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $40.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$32.96M
- EPS, diluted
- -$10.78
- Book value per share
- $25.07
- Diluted shares
- 5M
Trading
- Previous close
- $2.91
- Open
- $2.90
- Day's range
- $2.75 – $3.10
- Volume
- 870,101
- Average volume (20 days)
- 725,072
- Beta (5 years)
- 0.95
- 52-week range
- $2.75 – $36.99
- RSI (14 days)
- 33.1
- Volatility (1 year)
- 284.7%
- Relative volume
- 0.14×
- WACC
- 9.8%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.
| Period | GRML | S&P 500 | Difference | GRML per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.8% | -10.3% | −41.5 pts | ||
| 3 months | -64.0% | -9.3% | −54.7 pts | ||
| Year to date | -79.3% | +1.9% | −81.3 pts | ||
| 1 year | -85.1% | +6.9% | −92.0 pts | ||
| 3 years | -99.4% | +57.5% | −156.9 pts | -82.3% | +16.3% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Greenland Mines filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Update
- Update
About Greenland Mines
Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd, previously known as Klotho Neurosciences, Inc., is a biotechnology company focused on developing treatments for chronic illnesses, including neurodegenerative conditions, cancer, and cardiovascular diseases. Its product pipeline centers on proprietary gene and cell therapy candidates, specifically KLTO-101 for Alzheimer's disease and KLTO-202 for amyotrophic lateral sclerosis, which utilize the Klotho protein. Additionally, the company maintains licensed platforms comprising generic pharmaceuticals and biosimilar biologics targeting various solid tumors, and it operates an initiative focused on exploring and mining critical and precious minerals. Its therapeutics target adult and pediatric patient populations suffering from severe chronic disorders.
Company profile, executives and historyGreenland Mines stock: common questions
What is Greenland Mines's stock price?
GRML closed at $2.99 on Nov 20, 2026, up 2.75% on the day. Over the past 52 weeks it traded between $2.75 and $36.99.
What is Greenland Mines's market cap?
Greenland Mines was worth $40.92M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.
What is GRML's P/E ratio?
Greenland Mines lost money over fiscal 2025 (diluted EPS -$10.78), so it has no meaningful P/E ratio.
Does Greenland Mines pay a dividend?
No. Greenland Mines has not paid a cash dividend over the last twelve months.
How has GRML stock performed over the past year?
Including dividends, GRML returned -85.1% over the past year, against +6.9% for the S&P 500.
Who are Greenland Mines's competitors?
Companies most similar to Greenland Mines by business, industry and size include PASG, INMB, VYGR, MGTX, SGMOQ.
See a number that looks wrong?